Examkin

Soru

Zorluk: OrtaGynecologic Oncology

During a routine health maintenance visit, a 54-year-old G2P2 patient reports experiencing two days of light vaginal spotting the previous week. She underwent natural menopause at age 51. Her past medical history is significant for estrogen receptor-positive, node-negative breast cancer, for which she was treated with a lumpectomy and radiation therapy three years ago. Since completing her primary surgical and radiation treatment, she has been maintained on tamoxifen. Her body mass index is 26 kg/m^2. Vital signs are within normal limits. Pelvic examination demonstrates normal external genitalia, a small and mobile uterus, and no palpable adnexal masses. Speculum examination shows a small amount of dark red blood in the vaginal vault, but no active bleeding or visible cervical lesions. Which of the following is the most appropriate next step in management?

  1. Endometrial biopsyCevap
  2. B
    Reassurance and routine follow-up in six months
  3. C
    Immediate discontinuation of tamoxifen therapy
  4. D
    Cervical cytology and human papillomavirus testing
  5. E
    Total extrafascial hysterectomy and bilateral salpingo-oophorectomy

Cevap

Endometrial biopsy
The correct answer is endometrial biopsy. This patient presents with postmenopausal bleeding, which is abnormal and should always trigger an evaluation for endometrial cancer. Her risk is further elevated by her use of tamoxifen. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast tissue but as an estrogen agonist in the uterus. This agonistic effect promotes endometrial proliferation, increasing the risk of endometrial polyps, hyperplasia, and adenocarcinoma. The standard of care for postmenopausal bleeding is evaluation with either a transvaginal ultrasound or an endometrial biopsy. In a patient on tamoxifen, transvaginal ultrasound is often less useful because tamoxifen frequently causes subepithelial stromal hypertrophy, resulting in a falsely thickened endometrial stripe on imaging. Therefore, direct tissue sampling via endometrial biopsy is the most definitive and appropriate next step to rule out malignancy.

Adım Adım Çözüm

1
Identify the primary clinical problem and demographic risk factors.
The patient is a postmenopausal woman presenting with new-onset vaginal bleeding.
Postmenopausal bleeding is the cardinal symptom of endometrial cancer and requires immediate evaluation.
2
Analyze the impact of the patient's past medical history and medication use.
The patient takes tamoxifen for breast cancer, which acts as an estrogen agonist on the endometrium.
Tamoxifen significantly increases the risk of endometrial hyperplasia and endometrial adenocarcinoma.
3
Determine the most appropriate diagnostic intervention based on the clinical presentation.
Endometrial tissue sampling is required.
Because the risk of malignancy is high, direct histologic evaluation of the endometrium via biopsy is the standard of care to definitively rule in or rule out cancer.

Anahtar Kavram

Postmenopausal bleeding in a patient taking tamoxifen requires prompt evaluation with an endometrial biopsy to rule out endometrial hyperplasia or adenocarcinoma.
Bu soruyu puanla

Konular

Gynecologic Oncology

Bu konudan daha fazla soru